Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 6/20 | 0.37 |
| ▸ | CAMKK2 | Q96RR4 | 6/20 | 0.37 |
| ▸ | SGK1 | O00141 | 5/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 3/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.35 |
| ▸ | DYRK2 | Q92630 | 3/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.35 |
| ▸ | AURKA | O14965 | 1/20 | 0.35 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.35 |
| ▸ | SGK3 | Q96BR1 | 1/20 | 0.35 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.35 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12616725 | 0.88 | BTK (0.39) | AXLCAMKK2SGK1CCNT1CCNA2 | |
| SCHEMBL1799327 | 0.87 | MAP3K11 (0.44) | CYP3A4ROCK1 | |
| SCHEMBL1799017 | 0.86 | NTRK1 (0.44) | ROCK1 | |
| SCHEMBL1801628 | 0.78 | AXL (0.40) | AXLCAMKK2SGK1CCNT1CCNA2 | |
| SCHEMBL1796715 | 0.77 | AXL (0.61) | AXLCAMKK2SGK1CDK2DYRK1A | |
| SCHEMBL1801625 | 0.75 | AXL (0.40) | AXLCAMKK2SGK1CCNT1CCNA2 | |
| SCHEMBL1799923 | 0.74 | DYRK1A (0.50) | AXLCAMKK2SGK1CDK2CLK1 | |
| SCHEMBL2753124 | 0.73 | ALK (0.51) | — | |
| SCHEMBL3348998 | 0.71 | CAMKK2 (0.43) | CAMKK2SGK1CCNA2CDK2DYRK1A | |
| SCHEMBL1799783 | 0.71 | MAPK8 (0.38) | CAMKK2SGK1AURKACAMKK1SGK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951802-B2 | Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-18 | — | — | US | disclosed |
| WO-2008095943-A1 | THE USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | EISAI R&D MANAGEMENT CO. LTD. (JP) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069358-A1 | USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE | MAPK7, MAPKAPK5, MAPK13 | AXL 4302/4885CAMKK2 127/4885SGK1 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.